“Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture”
Published: 9 February 2021
by Allison Bakovic 1, Kenneth Risner 1OrcID, Nishank Bhalla 1, Farhang Alem 1OrcID, Theresa L. Chang 2, Warren K. Weston 3, Jane A. Harness 3 and Aarthi Narayanan 1,*
1
National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA
2
Public Health Research Institute, Rutgers, New Jersey Medical School, the State University of New Jersey, Newark, NJ 07103, USA
3
Innovation Pharmaceuticals Inc., Wakefield, MA 01880, USA
https://www.mdpi.com/1999-4915/13/2/271
Published: 9 February 2021
by Allison Bakovic 1, Kenneth Risner 1OrcID, Nishank Bhalla 1, Farhang Alem 1OrcID, Theresa L. Chang 2, Warren K. Weston 3, Jane A. Harness 3 and Aarthi Narayanan 1,*
1
National Center for Biodefense and Infectious Diseases, George Mason University, Manassas, VA 20110, USA
2
Public Health Research Institute, Rutgers, New Jersey Medical School, the State University of New Jersey, Newark, NJ 07103, USA
3
Innovation Pharmaceuticals Inc., Wakefield, MA 01880, USA
https://www.mdpi.com/1999-4915/13/2/271
4